Alzheimer’s drugs targeting amyloid β proteins “do not produce clinically meaningful positive effects” and slightly increase ...

STOCKHOLM, April 21, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Annual Report for 2025 has been published and is available on the company's website. The ...

According to MarketsandMarketstm, the global EMI shielding market is projected to grow from USD 8.04 billion in 2026 to USD 10.90 billion by 2032, registering a CAGR of ...

That's the conclusion of a just-published report (PDF) from the influential Institute for Clinical and Economic Review (ICER) ...

Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps ...

It's the latest in a long-running dispute over the drugs, which some view as groundbreaking, while others say they leave much ...

As the body ages, cells naturally accumulate dozens of genetic mutations each year. New research from Boston Children's Hospital, published in Cell, finds that the brain's resident immune cells, ...

Alzheimer’s disease, the leading cause of dementia, is a multifactorial disorder involving amyloid beta (Aβ) and tau ...

Mouse trials suggest this therapy could turn back the clock on aging brains, removing brain fog and restoring memory.

View the Daily Journal for Tuesday, April 21, 2026 ...

The FDA should strengthen the evidence required for drug approvals under its accelerated pathway and increase transparency ...

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux - a condition ...